Lyell Immunopharma, Inc. has disclosed a recent stock transaction involving its President and CEO, Seely Lynn. The filing indicates that Lynn sold 545 shares of common stock on November 10, 2026, at a price of $15.93 per share. This sale was made to cover tax withholding obligations from the settlement of vested restricted stock units.

This transaction is significant as it underscores the company's approach to managing executive compensation and stock ownership. Such actions are not uncommon in the pharmaceutical preparations industry, where executives often navigate complex stock compensation plans.

Background

Lyell Immunopharma, Inc. is a company focused on developing innovative immunotherapies for cancer treatment. It operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded on the Nasdaq under the ticker symbol LYEL. As a smaller reporting company, Lyell is subject to specific regulatory requirements but maintains a commitment to transparency in its operations.

What the Filing Says

The SEC filing, accession number 0001327111-26-000008, details that Seely Lynn executed a transaction to sell 545 shares of common stock. The filing notes, "Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units." Following this transaction, Lynn retains ownership of 63,354 shares.

Impact

This transaction may impact various stakeholders, including investors and analysts monitoring executive actions at Lyell Immunopharma. Such sales are often scrutinized as they can reflect the financial health of the company and the confidence of its leadership in its future performance.

What's Next

The filing does not say what happens next.